sci/r

NS309 是选择性钙依赖性钾离子通道 SK/IK 的激活剂，在 BK 通道上没有激活作用。

15-Acetoxyscirpenol, a member of the acetoxyscirpenol moiety mycotoxins (ASMs), potently induces apoptosis and inhibits the growth of Jurkat T cells in a dose-dependent manner. This effect is mediated through the activation of caspases independent of caspase-3[1].

Diacetoxyscirpenol (蛇形菌素)是一种霉菌毒素和真菌次生代谢物，能够抑制HIF-1，激活caspase-8，下调和cdk4和cyclin b1，抑制多种癌细胞生长。

Monoacetoxyscirpenol is a mycotoxin produced by Fusarium roseum Gibbosum.

Scirpusin A is a hydroxystilbene dimer from the rhizome of Scirpus fluviatilis and Xinjiang wine grape.

Scirpusin B (compound 5) 是从Scirpus maritimus L.中提取的一种二聚体抗氧化剂,具备多种生物活性,包括抗肿瘤、抗真菌、杀虫以及抑制植物生长的功能.

Keratanase II, bacillus circulans, expressed in E.coli 具有转糖基活性，能有效催化 α(2→3)-sialylated 6,6′-di-sulfo-LacNAc 与两种糖基受体：6-sulfo-Lewis X 和 6,6'-di-sulfo-LacNAc 衍生物，产生唾液酸磺基六糖和唾液酸磺基五糖。

Palmitic acid-1,2,3,4-13C4 is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid (T2908) is a common 16-carbon saturated fat that represents 10-20% of human dietary fat intake and comprises approximately 25 and 65% of human total plasma lipids and saturated fatty acids,respectively.1,2Acylation of palmitic acid to proteins facilitates anchoring of membrane-bound proteins to the lipid bilayer and trafficking of intracellular proteins,promotes protein-vesicle interactions,and regulates various G protein-coupled receptor functions.1Red blood cell palmitic acid levels are increased in patients with metabolic syndrome compared to patients without metabolic syndrome and are also increased in the plasma of patients with type 2 diabetes compared to individuals without diabetes.3,4

Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine (T20615) is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1

Avilamycin A is an antibiotic.1 It is active against veterinary isolates of C. perfringens (MICs = ≤0.06-0.5 mg/L) and B. hyodysenteriae (MICs = 12.5-100 μg/ml).1,2 Dietary administration of avilamycin A (15 and 30 ppm) reduces mortality in a broiler cockerel model of C. perfringens infection.3 Formulations containing avilamycin A have been used in the prevention of necrotic enteritis in livestock. |1. Watkins, K.L., Shryock, T.R., Dearth, R.N., et al. In-vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin. Vet. Microbiol. 54(2), 195-200 (1997).|2. Uezato, K., Kinjo, E., and Adachi, Y. In vitro susceptibility of 21 antimicrobial agents to 37 isolates of Brachyspira hyodysenteriae isolated from pigs in Okinawa Prefecture. J. Vet. Med. Sci. 66(3), 307-309 (2004).|3. Paradis, M.A., McMillan, E., Bagg, R., et al. Efficacy of avilamycin for the prevention of necrotic enteritis caused by a pathogenic strain of Clostridium perfringens in broiler chickens. Avian Pathol. 45(3), 365-369 (2016).

Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir (T2529) is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.